NK Cell Therapy for AML

NCT05256277 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped A new study is planed to replace the current study due to IP upgrade

Conditions

AML

Interventions

DRUG: CT101a

Sponsor

Zhejiang University

Collaborators

[object Object]